MMED

SEC source: 0001628280-26-017828 · wk-form4_1773444267.xml · nonDerivative · entry 1

Spooner Chad · CIK 0002111465 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,896

F1 · date: In connection with MMED's separation from Medtronic plc ("Medtronic") effective March 9, 2026 (the "Separation"), as further described in MMED's current report on Form 8-K filed on March 9, 2026, certain restricted stock units and performance share units granted by Medtronic held by the Reporting Person (the "Medtronic Awards") were converted into time-vesting restricted stock units denominated in shares of MMED's common stock ("MMED RSUs") pursuant to the terms of the Employee Matters Agreement, dated as of March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US HoldCo 2, Inc. (the "EMA").

F2 · date: Pursuant to the terms of the EMA, the Medtronic Awards were converted into MMED RSUs based, in part, on (i) the average closing trading price of a Medtronic ordinary share for the last three consecutive trading days ending on March 6, 2026 and (ii) the average closing trading price of a share of MMED common stock for three consecutive trading days starting with and including March 9, 2026 (the "Equity Award Conversion").

F3 · shares: Represents the grant of MMED RSUs upon the conversion of certain Medtronic Awards held by the Reporting Person pursuant to the Equity Award Conversion. The MMED RSUs were granted pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan (the "LTIP") and vest on April 28, 2028.

F3 · price: Represents the grant of MMED RSUs upon the conversion of certain Medtronic Awards held by the Reporting Person pursuant to the Equity Award Conversion. The MMED RSUs were granted pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan (the "LTIP") and vest on April 28, 2028.

F4 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units.

SEC source: 0001628280-26-016853 · wk-form4_1773261054.xml · derivative · entry 2

Gyurci John · CIK 0001850688 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,253

Underlying: Common Stock · 25,253 shares

Expires 2036-03-09

F3 · derivative.exercise_date: The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

SEC source: 0001628280-26-016853 · wk-form4_1773261054.xml · derivative · entry 1

Gyurci John · CIK 0001850688 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,778

Underlying: Common Stock · 2,778 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F1 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F2 · derivative.expiration_date: The later of March 9, 2027 or the Divestment Date.

SEC source: 0001628280-26-016854 · wk-form4_1773261060.xml · nonDerivative · entry 1

Lofton Kevin E · CIK 0001468818 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,778

F1 · shares: Represents restricted stock units that vest on the one-year anniversary of the grant date.

F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units.

SEC source: 0001628280-26-016855 · wk-form4_1773261066.xml · nonDerivative · entry 1

EISENBERG GLENN A · CIK 0001222831 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,889

F1 · shares: Represents restricted stock units that vest on the one-year anniversary of the grant date.

F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units.

SEC source: 0001628280-26-016856 · wk-form4_1773261072.xml · nonDerivative · entry 1

GROSSMAN D KEITH · CIK 0001218702 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,889

F1 · shares: Represents restricted stock units that vest on the one-year anniversary of the grant date.

F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units.

SEC source: 0001628280-26-016857 · wk-form4_1773261080.xml · nonDerivative · entry 1

Wicks Timothy A · CIK 0001339919 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,889

F1 · shares: Represents restricted stock units that vest on the one-year anniversary of the grant date.

F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units.

SEC source: 0001628280-26-016848 · wk-form4_1773261005.xml · derivative · entry 2

Dallara Que · CIK 0001756652 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,526

Underlying: Common Stock · 252,526 shares

Expires 2036-03-09

F3 · derivative.exercise_date: The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

SEC source: 0001628280-26-016848 · wk-form4_1773261005.xml · derivative · entry 1

Dallara Que · CIK 0001756652 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,334

Underlying: Common Stock · 83,334 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F1 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F2 · derivative.expiration_date: The later of March 9, 2027 or the Divestment Date.

SEC source: 0001628280-26-016852 · wk-form4_1773261048.xml · derivative · entry 2

Chandrasena Gillian · CIK 0002111466 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,132

Underlying: Common Stock · 63,132 shares

Expires 2036-03-09

F3 · derivative.exercise_date: The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

SEC source: 0001628280-26-016852 · wk-form4_1773261048.xml · derivative · entry 1

Chandrasena Gillian · CIK 0002111466 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,945

Underlying: Common Stock · 6,945 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F1 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F2 · derivative.expiration_date: The later of March 9, 2027 or the Divestment Date.

SEC source: 0001628280-26-016851 · wk-form4_1773261042.xml · derivative · entry 2

Wills Courtney Nelson · CIK 0002110477 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,132

Underlying: Common Stock · 63,132 shares

Expires 2036-03-09

F3 · derivative.exercise_date: The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

SEC source: 0001628280-26-016851 · wk-form4_1773261042.xml · derivative · entry 1

Wills Courtney Nelson · CIK 0002110477 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,945

Underlying: Common Stock · 6,945 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F1 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F2 · derivative.expiration_date: The later of March 9, 2027 or the Divestment Date.

SEC source: 0001628280-26-016850 · wk-form4_1773261034.xml · derivative · entry 2

Dianaty Ali · CIK 0002111492 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,263

Underlying: Common Stock · 126,263 shares

Expires 2036-03-09

F3 · derivative.exercise_date: The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

SEC source: 0001628280-26-016850 · wk-form4_1773261034.xml · derivative · entry 1

Dianaty Ali · CIK 0002111492 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,889

Underlying: Common Stock · 13,889 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F1 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F2 · derivative.expiration_date: The later of March 9, 2027 or the Divestment Date.

SEC source: 0001628280-26-016849 · wk-form4_1773261026.xml · derivative · entry 2

Spooner Chad · CIK 0002111465 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,176

Underlying: Common Stock · 84,176 shares

Expires 2036-03-09

F3 · derivative.exercise_date: The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

SEC source: 0001628280-26-016849 · wk-form4_1773261026.xml · derivative · entry 1

Spooner Chad · CIK 0002111465 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,778

Underlying: Common Stock · 27,778 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F1 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

F2 · derivative.expiration_date: The later of March 9, 2027 or the Divestment Date.